Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu AF28996 open-label exploratory study in Parkinson's disease
NL-OMON52830Completed
- Sponsor
- Lundbeck
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of Lu AF28996 in Parkinson's disease (PD), sponsored by Lundbeck. Primary endpoints: Treatment-emergent adverse events, Cmax of Lu AF28996 and 2 more. Started Oct 2020; status: completed.
02
Drugs
Lu AF28996
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NL-OMON52830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52830.